DANA HONG: Open Payments
NPI 1073017604 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,325 in 180 payments from 21 companies in 2025. Trend: 2023 $885 · 2024 $4,525 · 2025 $4,325
Food & beverage: $4,325
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $911 |
| Janssen Biotech, Inc. | 18 | $715 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $602 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $257 |
| Celltrion USA Inc. | 8 | $238 |
| Regeneron Healthcare Solutions, Inc. | 7 | $212 |
| Madrigal Pharmaceuticals | 11 | $189 |
| GENZYME CORPORATION | 5 | $148 |
| Phathom Pharmaceuticals, Inc. | 3 | $146 |
| QOL Medical, LLC | 5 | $126 |
Products named: TREMFYA, DUPIXENT, RINVOQ, ENTYVIO, XIFAXAN, ARALAST, REZDIFFRA, SKYRIZI.
Industry payments across TX — which companies pay providers there.
